Skip to main content
Kaysia Ludford, MD, Internal Medicine, Boston, MA, Harris Health System

KaysiaLudfordMD

Internal Medicine Boston, MA

Hematology/Oncology

Physician

Dr. Ludford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ludford's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2014 - 2017
  • Yale School of Medicine
    Yale School of MedicineClass of 2014

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2019 - 2025
  • AZ State Medical License
    AZ State Medical License 2022 - 2025
  • TN State Medical License
    TN State Medical License 2022 - 2025
  • WA State Medical License
    WA State Medical License 2022 - 2025
  • LA State Medical License
    LA State Medical License 2022 - 2024
  • OK State Medical License
    OK State Medical License 2022 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Publications & Presentations

PubMed

Lectures

  • Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment
    Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer TreatmentFebruary 23rd, 2023

Hospital Affiliations